Vident Investment Advisory LLC bought a new stake in Iqvia Holdings Inc (NYSE:IQV) in the 4th quarter, HoldingsChannel.com reports. The fund bought 5,755 shares of the medical research company’s stock, valued at approximately $563,000.
A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in Iqvia in the 4th quarter valued at approximately $942,532,000. Longview Partners Guernsey LTD acquired a new stake in Iqvia in the 4th quarter valued at approximately $927,548,000. Jackson Square Partners LLC acquired a new stake in Iqvia in the 4th quarter valued at approximately $464,053,000. Farallon Capital Management LLC acquired a new stake in Iqvia in the 4th quarter valued at approximately $290,072,000. Finally, Alliancebernstein L.P. acquired a new position in shares of Iqvia in the fourth quarter worth $253,128,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.
Several research firms have commented on IQV. Zacks Investment Research downgraded shares of Iqvia from a “buy” rating to a “hold” rating in a research note on Friday, January 19th. JPMorgan Chase & Co. boosted their price target on shares of Iqvia from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. ValuEngine upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a research note on Tuesday, February 20th. Royal Bank of Canada set a $118.00 price target on shares of Iqvia and gave the stock a “buy” rating in a research note on Thursday, February 15th. Finally, TheStreet upgraded shares of Iqvia from a “c+” rating to a “b” rating in a research note on Wednesday, December 13th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. Iqvia has a consensus rating of “Buy” and a consensus target price of $110.02.
Shares of Iqvia stock opened at $99.72 on Friday. The stock has a market cap of $20,768.69, a price-to-earnings ratio of 16.48, a PEG ratio of 1.44 and a beta of 0.64. Iqvia Holdings Inc has a 1 year low of $77.16 and a 1 year high of $110.67. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.19 and a current ratio of 1.19.
Iqvia (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.34 by ($0.02). The firm had revenue of $2.16 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Iqvia had a return on equity of 13.03% and a net margin of 13.44%. Iqvia’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same period last year, the firm posted $1.09 earnings per share. research analysts anticipate that Iqvia Holdings Inc will post 5.02 earnings per share for the current year.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.